Vicore Pharma Holding AB

NASDAQ:VCRE

Medical - Pharmaceuticals

Healthcare
$9.90 -1.66%

-$0.24 today

Market cap
$279.65M
Beta
0.15

Volume 0.00M

Average 0.26M

VCRE Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

Vicore Pharma Holding ABNASDAQ: VCRE

Net Debt · Q2 FY2026 · quarter ended Jun 2026

Net debt of -SEK 44.2M in Q2 FY2026

Q2 FY2026 net debt was -SEK 44.2M.

Context

  • Net debt amounted to 46.1% of total assets at the end of Q2 FY2026.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
-SEK 44.2M+88.3% QoQ
Last fiscal yearDec 2025
-SEK 578.15M— YoY
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Debt history

SEK · from the balance sheet

Latest · FY2025
(578.15M) SEK
Year-over-year change
—

Net Debt vs competitors

How VCRE compares with its peers on the latest reported figures

  • Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
  • Net debt amounts to 46.1% of total assets for VCRE, versus a peer median of 29.7%.
VCRE Competitors
Net Debt for VCRE and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
VCREVicore Pharma Holding ABJun 2026-SEK 44.2M SEK——46.1%
LQDALiquidia CorporationJun 2026-$155.24M USD-675.8%—29.7%
AVLNAvalyn Pharma Inc. Common Stock—— ———
Peer median (excluding VCRE) —-675.8%—29.7%

Competitors are the stored peer set for VCRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Vicore Pharma Holding AB

NASDAQ:VCRE

Intrinsic Alpha fair value

Locked

Current Price

$9.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.